| Literature DB >> 33840168 |
Sarmilah Mathavan1, Chin Siang Kue1, Suresh Kumar1.
Abstract
Lip and oral cavity cancer, which can occur in any part of the mouth, is the 11th most common type of cancer worldwide. The major obstacles to patients' survival are the poor prognosis, lack of specific biomarkers, and expensive therapeutic alternatives. This study aimed to identify the main genes and pathways associated with lip and oral cavity carcinoma using network analysis and to analyze its molecular mechanism and prognostic significance further. In this study, 472 genes causing lip and oral cavity carcinoma were retrieved from the DisGeNET database. A protein-protein interaction network was developed for network analysis using the STRING database. VEGFA, IL6, MAPK3, INS, TNF, MAPK8, MMP9, CXCL8, EGF, and PTGS2 were recognized as network hub genes using the maximum clique centrality algorithm available in cytoHubba, and nine potential drug candidates (ranibizumab, siltuximab, sulindac, pomalidomide, dexrazoxane, endostatin, pamidronic acid, cetuximab, and apricoxib) for lip and oral cavity cancer were identified from the DGIdb database. Gene enrichment analysis was also performed to identify the gene ontology categorization of cellular components, biological processes, molecular functions, and biological pathways. The genes identified in this study could furnish a new understanding of the underlying molecular mechanisms of carcinogenesis and provide more reliable biomarkers for early diagnosis, prognostication, and treatment of lip and oral cavity cancer.Entities:
Keywords: biomarkers; carcinogenesis; lip neoplasms; mouth neoplasms; prognosis
Year: 2021 PMID: 33840168 PMCID: PMC8042300 DOI: 10.5808/gi.20062
Source DB: PubMed Journal: Genomics Inform ISSN: 1598-866X
Fig. 1.Protein-protein interaction network overview built using STRING in Cytoscape. The network consists of 8,573 edges (interactions) between 444 nodes based on a confidence score of 0.4 and the maximum additional interactors default parameter. Nodes represent proteins, edges represent the interaction between two nodes (proteins).
The top 10 ranked nodes were selected using the MCC method in the cytoHubba app in Cytoscape 3.7.2
| Rank | Gene name | MCC score |
|---|---|---|
| 1 | 1.88148120178673E+37 | |
| 2 | 1.88148120178002E+37 | |
| 3 | 1.88148120172653E+37 | |
| 4 | 1.88148118653989E+37 | |
| 5 | 1.88148116290353E+37 | |
| 6 | 1.88148112775536E+37 | |
| 7 | 1.88147822258162E+37 | |
| 8 | 1.88147770682472E+37 | |
| 9 | 1.88147075212715E+37 | |
| 10 | 1.88128391642781E+37 |
These top 10 ranked nodes represent the top 10 hub genes of lip and oral cavity carcinoma.
Based on these results, VEGFA was identified as the highest-ranked hub gene with the highest maximum clique centrality (MCC) score.
Fig. 2.The protein-protein interaction subnetwork consisting of 10 hub genes based on the maximum clique centrality scoring method ranking. The network of the 10 hub genes is shown with red (high ranking) and yellow nodes (low ranking) based on the ranking score.
Fig. 3.Gene enrichment analysis of 10 significant hub genes (false discovery rate ≤ 0.05) based on the gene ontology slim summary using WebGestalt. (A) Gene enrichment analysis of 10 recognized hub genes based on biological processes. (B) Gene enrichment analysis of 10 recognized hub genes based on cellular components. (C) Gene enrichment analysis of 10 recognized hub genes based on molecular function.
Fig. 4.Gene enrichment analysis of 10 recognized significant hub genes (false discovery rate [FDR] ≤ 0.05) based on the biological pathways of the Reactome database.
Antineoplastic drugs targeting the predicted hub genes for lip and oral cavity cancer based on the DGIdb database
| Hub gene | Drug | Type | Source | Interaction score |
|---|---|---|---|---|
| VEGFA | Ranibizumab | Inhibitor | DrugBank, TdgClinicalTrial, ChemblInteractions, TEND, PharmGKB TTD | 6.51 |
| IL6 | Siltuximab | Inhibitor | DrugBank, MyCancerGenome, ChemblInteractions, TTD | 8.61 |
| MAPK3 | Sulindac | Inhibitor | DrugBank | 0.34 |
| INS | - | - | - | No interaction |
| TNF | Pomalidomide | Inhibitor | DrugBank | 0.22 |
| MAPK8 | Dexrazoxane | - | NCI | 0.39 |
| MMP9 | Endostatin | - | DrugBank | 0.82 |
| CXCL8 | Pamidronic acid | NCI | 0.39 | |
| EGF | Cetuximab | CIViC, PharmGKB | ||
| 1.16 | ||||
| PTGS2 | Apricoxib | Inhibitor | TALC, TdgClinicalTrial, ChemblInteractions | 1.39 |
The interaction score was calculated from the DGIdb database based on the evidence score and relative drug and gene specificity. The table shows small-molecule drugs with potential therapeutic effects for lip and oral cavity cancer based on the highest interaction score for each predicted hub gene.